APA

Peterfy C., DiCarlo J., Emery P., Genovese M. C., Keystone E. C., Taylor P. C., Schlichting D. E., Beattie S. D., Luchi M. & Macias W. (20200916). MRI and Dose Selection in a Phase II Trial of Baricitinib with Conventional Synthetic Disease-modifying Antirheumatic Drugs in Rheumatoid Arthritis. : The Journal of rheumatology.

Chicago

Peterfy Charles, DiCarlo Julie, Emery Paul, Genovese Mark C, Keystone Edward C, Taylor Peter C, Schlichting Doug E, Beattie Scott D, Luchi Monica and Macias William. 20200916. MRI and Dose Selection in a Phase II Trial of Baricitinib with Conventional Synthetic Disease-modifying Antirheumatic Drugs in Rheumatoid Arthritis. : The Journal of rheumatology.

Harvard

Peterfy C., DiCarlo J., Emery P., Genovese M. C., Keystone E. C., Taylor P. C., Schlichting D. E., Beattie S. D., Luchi M. and Macias W. (20200916). MRI and Dose Selection in a Phase II Trial of Baricitinib with Conventional Synthetic Disease-modifying Antirheumatic Drugs in Rheumatoid Arthritis. : The Journal of rheumatology.

MLA

Peterfy Charles, DiCarlo Julie, Emery Paul, Genovese Mark C, Keystone Edward C, Taylor Peter C, Schlichting Doug E, Beattie Scott D, Luchi Monica and Macias William. MRI and Dose Selection in a Phase II Trial of Baricitinib with Conventional Synthetic Disease-modifying Antirheumatic Drugs in Rheumatoid Arthritis. : The Journal of rheumatology. 20200916.